Generic Name: cabotegravir

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Integrase Inhibitors

Company: ViiV Healthcare

Approval Status: Experimental

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Cabotegravir is being studied as a pill for HIV treatment and as a long-acting HIV injectable for pre-exposure prophylaxis (PrEP). It has not yet been reviewed for inclusion in the DHHS list of recommended medications for HIV treatment or prevention.

General Info

Cabotegravir is an experimental integrase inhibitor. It is currently in Phase III clinical trials as a long-acting injectable medication for pre-exposure prophylaxis (PrEP). A combination of cabotegravir and another long-acting injectable, rilpivirine, is in Phase III trials as an all-in-one HIV treatment regimen. A pill form of cabotegravir is being studied as a lead-in medication for people who want to use the long-acting injectable combination.


Dosing Info:

This is a long-acting injectable HIV medication administered every four or eight weeks.

Side Effects


Other Info

Last Reviewed: October 11, 2019